Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.40 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700129 | 0.88 | LMNA (0.51) | PARP1ENPP1HDAC1 | |
| SCHEMBL4699220 | 0.85 | PARP1 (0.60) | PARP1ENPP1CYP3A4CYP2C9TSHR | |
| SCHEMBL4702676 | 0.85 | PARP1 (0.48) | PARP1ENPP1HDAC1 | |
| SCHEMBL4704345 | 0.82 | PARP1 (0.58) | PARP1 | |
| SCHEMBL4699250 | 0.82 | MAPT (0.53) | PARP1ENPP1TNKSTNKS2 | |
| SCHEMBL4697402 | 0.81 | PARP1 (0.57) | PARP1 | |
| SCHEMBL4699801 | 0.80 | MAPT (0.49) | PARP1ENPP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4699720 | 0.80 | PARP1 (0.53) | PARP1ENPP1TNKSPARP14PARP10 | |
| SCHEMBL4700818 | 0.80 | CYP3A4 (0.53) | PARP1ENPP1CYP3A4CYP2C9TSHR | |
| SCHEMBL4700454 | 0.79 | MAPT (0.60) | PARP1ENPP1HDAC1TNKSPARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432263-B2 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA, S.R.L. (IT) | 2008-10-07 | — | — | US | claimed |
| EP-1427708-B1 | AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2008-09-10 | — | — | EP | claimed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | claimed |
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-17 | — | — | US | claimed |
| US-7432263-B2 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA, S.R.L. (IT) | 2008-10-07 | — | — | US | disclosed |
| EP-1427708-B1 | AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2008-09-10 | — | — | EP | disclosed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | disclosed |
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K15, MAP3K5 | PARP1 1385/4885ENPP1 1105/4885HDAC1 608/4885 |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K1, MAP3K15 | PARP1 1467/4885ENPP1 952/4885HDAC1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.